Now showing items 1-5 of 5
Subtypes of nonmedical opioid users: results from the national epidemiologic survey on alcohol and related conditions.
(Drug and alcohol dependence, 2010-11)
To identify subtypes of nonmedical opioid users, gender variations in psychiatric disorders, and quality of life in a representative sample of adults.Analyses of data from the 2001-2002 National Epidemiologic Survey on Alcohol ...
How do prescription opioid users differ from users of heroin or other drugs in psychopathology: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
(Journal of addiction medicine, 2011-03)
To study substance use and psychiatric disorders among prescription opioid users, heroin users, and non-opioid drug users in a national sample of adults.Analyses of data from the 2001-2002 National Epidemiologic Survey on ...
Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network.
(Drug and alcohol dependence, 2011-11)
BACKGROUND:This study applied item response theory (IRT) and latent class analysis (LCA) procedures to examine the dimensionality and heterogeneity of comorbid substance use disorders (SUDs) and explored their utility for ...
Alcohol and drug dependence symptom items as brief screeners for substance use disorders: results from the Clinical Trials Network.
(Journal of psychiatric research, 2012-03)
AIM:To address an urgent need for screening of substance use problems in medical settings, we examined substance-specific dependence criteria as potential brief screeners for the detection of patients with a substance use ...
Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
(Drug and alcohol dependence, 2014-05)
The approval of extended release injectable naltrexone (XR-NTX; Vivitrol(®)) has introduced a new option for treating opioid addiction, but studies are needed to identify its place within the spectrum of available therapies. ...